Fund Details

Cormorant Asset Management
200 Clarendon Street, 52nd Floor, Boston, MA, 02116, United States
Overview
Investment portfolio
211rounds
| NAME | DATE | SIZE | |
|---|---|---|---|
Epicrispr | Aug 2026Participated | $90 MSeries C | |
Crystalys Therapeutics | Jul 2026Participated | $130 MSeries B | |
Terremoto Biosciences | Apr 2026Participated | $108 MSeries C | |
Candid Therapeutics | Mar 2026Participated | $505 MOther Equity | |
Parabilis Medicines | Jan 2026Participated | $305 MSeries F | |
BlossomHill Therapeutics | Dec 2025Participated | $84 MSeries B | |
Aspen Neuroscience | Nov 2025Participated | $115 MSeries C | |
Ensoma | Sep 2025Participated | $53 MOther Equity | |
Antares Therapeutics | Jun 2025Led | $177 MSeries A | |
Fore Biotherapeutics | May 2025Participated | $38 MSeries D | |
Attovia Therapeutics | Apr 2025Participated | $90 MSeries C | |
Supira Medical | Mar 2025Participated | $120 MSeries E | |
Epicrispr | Aug 2026Participated | $90 MSeries C | |
Crystalys Therapeutics | Jul 2026Participated | $130 MSeries B | |
Terremoto Biosciences | Apr 2026Participated | $108 MSeries C | |
Candid Therapeutics | Mar 2026Participated | $505 MOther Equity | |
Parabilis Medicines | Jan 2026Participated | $305 MSeries F | |
BlossomHill Therapeutics | Dec 2025Participated | $84 MSeries B | |
Aspen Neuroscience | Nov 2025Participated | $115 MSeries C | |
Ensoma | Sep 2025Participated | $53 MOther Equity | |
Antares Therapeutics | Jun 2025Led | $177 MSeries A | |
Fore Biotherapeutics | May 2025Participated | $38 MSeries D | |
Attovia Therapeutics | Apr 2025Participated | $90 MSeries C | |
Supira Medical | Mar 2025Participated | $120 MSeries E |
211 Items
211
Items
...
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Series A | 13 | 24 |
| Series B | 14 | 59 |
| Series C+ | 11 | 70 |
| Other Equity | 5 | 14 |
| Debt | 0 | 1 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Apr '15 | 2 |
| May '15 | 1 |
| Jun '15 | 2 |
| Jul '15 | 1 |
| Aug '15 | 3 |
| Sep '15 | 2 |
| Oct '15 | 1 |
| Nov '15 | 0 |
| Dec '15 | 4 |
| Jan '16 | 2 |
| Feb '16 | 1 |
| Mar '16 | 2 |
| Apr '16 | 0 |
| May '16 | 1 |
| Jun '16 | 1 |
| Jul '16 | 0 |
| Aug '16 | 1 |
| Sep '16 | 0 |
| Oct '16 | 0 |
| Nov '16 | 0 |
| Dec '16 | 0 |
| Jan '17 | 0 |
| Feb '17 | 0 |
| Mar '17 | 2 |
| Apr '17 | 0 |
| May '17 | 1 |
| Jun '17 | 1 |
| Jul '17 | 2 |
| Aug '17 | 2 |
| Sep '17 | 2 |
| Oct '17 | 1 |
| Nov '17 | 2 |
| Dec '17 | 0 |
| Jan '18 | 1 |
| Feb '18 | 1 |
| Mar '18 | 1 |
| Apr '18 | 6 |
| May '18 | 0 |
| Jun '18 | 3 |
| Jul '18 | 0 |
| Aug '18 | 2 |
| Sep '18 | 2 |
| Oct '18 | 2 |
| Nov '18 | 1 |
| Dec '18 | 3 |
| Jan '19 | 0 |
| Feb '19 | 2 |
| Mar '19 | 1 |
| Apr '19 | 2 |
| May '19 | 1 |
| Jun '19 | 1 |
| Jul '19 | 0 |
| Aug '19 | 0 |
| Sep '19 | 0 |
| Oct '19 | 0 |
| Nov '19 | 1 |
| Dec '19 | 1 |
| Jan '20 | 1 |
| Feb '20 | 1 |
| Mar '20 | 4 |
| Apr '20 | 2 |
| May '20 | 1 |
| Jun '20 | 3 |
| Jul '20 | 4 |
| Aug '20 | 3 |
| Sep '20 | 5 |
| Oct '20 | 3 |
| Nov '20 | 3 |
| Dec '20 | 3 |
| Jan '21 | 6 |
| Feb '21 | 3 |
| Mar '21 | 10 |
| Apr '21 | 4 |
| May '21 | 3 |
| Jun '21 | 4 |
| Jul '21 | 3 |
| Aug '21 | 1 |
| Sep '21 | 4 |
| Oct '21 | 1 |
| Nov '21 | 2 |
| Dec '21 | 1 |
| Jan '22 | 3 |
| Feb '22 | 5 |
| Mar '22 | 0 |
| Apr '22 | 1 |
| May '22 | 2 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 1 |
| Sep '22 | 1 |
| Oct '22 | 1 |
| Nov '22 | 1 |
| Dec '22 | 0 |
| Jan '23 | 1 |
| Feb '23 | 2 |
| Mar '23 | 3 |
| Apr '23 | 1 |
| May '23 | 1 |
| Jun '23 | 1 |
| Jul '23 | 1 |
| Aug '23 | 3 |
| Sep '23 | 1 |
| Oct '23 | 2 |
| Nov '23 | 1 |
| Dec '23 | 0 |
| Jan '24 | 1 |
| Feb '24 | 4 |
| Mar '24 | 2 |
| Apr '24 | 0 |
| May '24 | 5 |
| Jun '24 | 0 |
| Jul '24 | 3 |
| Aug '24 | 1 |
| Sep '24 | 1 |
| Oct '24 | 2 |
| Nov '24 | 0 |
| Dec '24 | 1 |
| Jan '25 | 2 |
| Feb '25 | 0 |
| Mar '25 | 3 |
| Apr '25 | 1 |
| May '25 | 1 |
| Jun '25 | 1 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 1 |
| Oct '25 | 0 |
| Nov '25 | 1 |
| Dec '25 | 1 |
| Jan '26 | 1 |
| Feb '26 | 0 |
| Mar '26 | 1 |
| Apr '26 | 1 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 1 |
| Aug '26 | 1 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 208 |
| Manufacturing | 8 |
| Consumer & Lifestyle | 6 |
| Enterprise Software | 3 |
| Space & Frontier Tech | 3 |
| Hardware & Robotics | 3 |
| Developer Tools | 3 |
| Data, Analytics & IT | 2 |
| AI & Machine Learning | 2 |
| Food & Agriculture | 2 |
| Professional Services | 2 |
| Clean Energy & Sustainability | 1 |
| Real Estate & Construction | 1 |
| Networks, Cloud & Communication | 1 |
| Social & Community Platforms | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 1 |
| $10M-$25M | 14 |
| $25M-$50M | 35 |
| $50M-$100M | 78 |
| $100M-$250M | 75 |
| $250M-$500M | 7 |
| $500M-$1B | 1 |
| $1B+ | 0 |
Deals By Geography
Top 4 of 4 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 192 |
| Europe | 11 |
| China | 7 |
| Australia | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Janus Henderson Investors | 44 |
| RA Capital Management | 41 |
| OrbiMed | 40 |
| Surveyor Capital | 36 |
| Logos Capital | 34 |
| Wellington Management | 30 |
| HBM Healthcare Investments | 26 |
| Redmile Group | 25 |
| Rock Springs Capital | 25 |
| Alexandria Venture Investments | 24 |
| T. Rowe Price Associates | 24 |
| Casdin Capital | 23 |
| venBio Partners | 23 |
| Perceptive Advisors | 22 |
| Fidelity Management & Research Company | 20 |
| Foresite Capital | 20 |
| RTW Investments | 20 |
| Venrock | 20 |
| Vivo Capital | 19 |
| BVF Partners | 18 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 43 | 20% |
| Participating | 168 | 80% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 18 | 42% |
| Co-led | 25 | 58% |